CXCL12 binds directly to tenascin-C, and pharmacological inhibition of the CXCL12-CXCR4 signaling, using the CXCR4 receptor antagonist AMD3100, releases tumor-infiltrating lymphocytes from their matrix-mediated arrest (47), demonstrating the importance of the CXCL12-tenascin-C interaction in lymphocyte migration. The gene discussed is CXCR4; the disease is neoplasm.